Overview

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-03-31

Target enrollment:

Participant gender:

Summary

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Phase:

PHASE4

Details

Lead Sponsor:

Mayo Clinic

Treatments:

semaglutide
Tirzepatide